FDA Regulations on Exosome Products in 2026: What Physicians Need to Know

Published March 2026 | BioRegenEx Compliance Team | 7-minute read

The question we get most often from physicians interested in exosome therapy is: “Is this FDA-approved?” The answer, like many things in regenerative medicine, requires nuance. This guide summarizes the current federal regulatory framework for exosome products, what compliance looks like in 2026, and what every physician should verify before sourcing exosomes for their practice.

The Short Answer: Exosomes Are Not FDA-Approved Drugs — But That’s Not the Whole Story

No exosome product has completed the full FDA drug approval process (NDA or BLA) as of early 2026. However, this does not mean all exosome use is illegal or unregulated. The regulatory picture depends on how a product is manufactured, labeled, and used.

The Regulatory Framework: HCT/Ps Under 21 CFR Part 1271

Most MSC-derived exosome products are regulated under 21 CFR Part 1271, which governs Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Under this framework, products that meet specific criteria may be commercially distributed without a Biologics License Application (BLA), as long as they comply with registration, listing, and good tissue practice requirements.

The two key criteria for the “361 HCT/P” pathway (which requires minimal FDA oversight) are:

• Minimal manipulation: The product’s relevant biological characteristics are not altered during processing
• Homologous use: The product performs the same basic function in the recipient as it does in the donor

Products that do not meet both criteria are regulated as drugs and/or biological products, requiring an Investigational New Drug (IND) application and ultimately a BLA for commercial marketing.

The FDA’s Enforcement Posture: What Changed After 2024

In 2021, the FDA’s enforcement discretion period for HCT/P products officially ended, signaling increased regulatory scrutiny of regenerative medicine products including exosomes. In 2023, Kimera Labs — one of the most prominent exosome manufacturers — received an FDA Warning Letter. This underscored that the regulatory environment is actively evolving and that supplier compliance matters significantly.

In 2025–2026, the FDA has continued to pursue enforcement actions against manufacturers making unsubstantiated claims, operating without proper registration, or distributing products that do not meet HCT/P standards. Physicians sourcing from non-compliant manufacturers expose themselves and their patients to risk.

What Physicians Must Verify About Their Exosome Supplier

As a prescribing or administering physician, you share responsibility for ensuring the products you use in your practice meet applicable standards. Here is a practical compliance checklist:

1. FDA registration: Verify that the supplier is registered with the FDA as a HCT/P establishment. Registration can be confirmed at the FDA’s HCT/P registration database.
2. Current Good Tissue Practice (cGTP) compliance: The supplier should operate under cGTP regulations (21 CFR Part 1271 Subpart D). Request documentation of their GTP compliance program.
3. Certificate of Analysis: Every lot should have a complete CoA including particle count, sterility testing, endotoxin levels, and exosome marker characterization.
4. Labeling compliance: Products must be labeled per 21 CFR Part 1271.370 requirements. Verify that no drug claims are made in product labeling or marketing materials.
5. Donor screening and testing: Confirm that donors were screened and tested per 21 CFR Part 1271.80 requirements.
6. Adverse event reporting: Verify the supplier has an adverse event reporting protocol per 21 CFR Part 1271.350.

What About Physicians Who Administer Exosomes? Do They Need an IND?

A physician practicing within the physician-patient relationship, using a properly manufactured HCT/P product consistent with its labeling, is generally not required to hold an IND under the physician’s practice exception. However, this exception has limits — particularly when exosome administration is part of a structured clinical trial, marketed as a treatment, or involves claims that go beyond the product’s labeled use.

Physicians should be particularly cautious about:

• Making specific disease treatment claims in marketing materials
• Offering exosome therapy for conditions where the evidence base is limited or absent
• Using products not manufactured by FDA-registered facilities
• Participating in or directing clinical protocols without appropriate IRB oversight where required

The Clinical Trial Landscape in 2026

The exosome space is rapidly maturing from a regulatory standpoint. As of 2026, multiple exosome-based therapeutics have entered Phase I and Phase II clinical trials with FDA IND clearance. These include applications in cardiovascular disease, graft-versus-host disease, and neurodegenerative conditions. This clinical trial activity is generating the FDA safety data that will eventually support product approvals — and is also setting the regulatory expectations for the entire category.

Physicians staying informed about trial outcomes will be best positioned as the FDA’s guidance on exosome products continues to evolve.

How BioRegenEx Supports Physician Compliance

BioRegenEx takes a compliance-first approach to everything we do. Our physician partners receive:

• Full Certificate of Analysis with every order
• FDA registration documentation and facility information
• Product-specific regulatory guidance documentation
• Clear labeling that does not make drug claims
• A dedicated compliance support contact for questions

We also provide access to our 229-study peer-reviewed research library, which helps physicians make evidence-based decisions about where exosome therapy has the strongest scientific support.

Key Takeaways for 2026

• Exosomes are not FDA-approved drugs, but they can be legally supplied and used under the HCT/P regulatory framework when manufactured compliantly
• The FDA is actively enforcing against non-compliant manufacturers — supplier vetting is critical
• Physicians bear responsibility for ensuring they source from FDA-registered, cGTP-compliant manufacturers
• Clinical trials are advancing and will continue to shape the regulatory landscape
• BioRegenEx provides full compliance documentation as a standard part of our physician portal program

Frequently Asked Questions

Is exosome therapy FDA approved?

No. As of 2026, FDA has not approved any exosome product for any indication. FDA said so directly in its December 2019 public safety notification and has repeated it in warning letters since. Exosome products marketed to treat or prevent disease are unapproved drugs and biologics under Section 351 of the Public Health Service Act.

Are exosomes FDA approved for any condition at all?

No condition, route, or product has an approval. Some sponsors are running clinical trials under an Investigational New Drug application, but an IND allows study, not marketing. If a product ever receives a Biologics License Application, that approval will apply to that specific product for the specific indication studied, and to nothing else.

What does "FDA registered" mean on an exosome supplier's website?

It means the facility has filed a registration with FDA under 21 CFR Part 1271, which any establishment that manufactures HCT/Ps is required to do. Registration is a filing, not a review, and it says nothing about whether a product is approved, safe, or effective. A supplier who presents registration as approval is describing the regulation incorrectly.

Can a physician legally administer exosomes to patients?

Administering an exosome product to treat a condition is use of an unapproved biologic. The lawful route to clinical use is an IND with an IRB-approved protocol and informed consent that discloses the investigational status. Outside an IND, exosome material is supplied for research use only, and physicians should expect their state medical board to have a position on unapproved regenerative products.

What is the difference between Section 361 and Section 351?

Section 361 products meet all four criteria in 21 CFR 1271.10(a): minimal manipulation, homologous use, no combination with another article, and no systemic effect or dependence on living cells unless autologous or related-donor use. They need registration and Good Tissue Practice but no premarket approval. Section 351 products fail at least one criterion and are regulated as drugs and biologics requiring an IND and a BLA. Exosome products fail the first two criteria and fall under 351. Our 361 vs 351 guide walks through each criterion.

What should a Certificate of Analysis for exosomes include?

At minimum: lot number, particle concentration and size distribution (typically by nanoparticle tracking analysis), sterility, endotoxin, mycoplasma, and the identity markers tested, with the name of the third-party laboratory that ran the tests. A COA issued by the seller rather than an independent lab, or one without a lot number, is a warning sign. See how to read a COA.

Has FDA taken enforcement action against exosome companies?

Yes. Following the 2019 Nebraska adverse events, FDA issued its public safety notification and has since sent warning letters to companies marketing exosome products with therapeutic claims. The common thread in every action is the claim: products marketed as treatments for disease are treated as unapproved biologics regardless of how the label describes them.